Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase 3, double-blind, randomised, placebo-controlled trial-Reference-Cited by-同舟云学术

Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase 3, double-blind, randomised, placebo-controlled trial

Published:2023-06 Issue:6 Volume:22 Page:476-484
ISSN:1474-4422
Container-title:The Lancet Neurology
language:en
Short-container-title:The Lancet Neurology

Author:

Yu Shengyuan,Kim Byung-Kun,Guo Aihong,Kim Man-Ho,Zhang Mingjie,Wang Zhen,Liu Jianguang,Moon Heui-Soo,Tan Ge,Yang Qian,McGrath Donnie,Hanna Michael,Stock David A,Gao Yanfei,Croop Robert,Lu Zhihong

Publisher

Elsevier BV

Subject

Neurology (clinical)

Reference26 articles.

1. The International Classification of Headache Disorders. 3rd edition;Cephalalgia,2018

2. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019;Vos;Lancet,2020

3. Burden of headache disorders in China, 1990-2017: findings from the Global Burden of Disease Study 2017;Yao;J Headache Pain,2019

4. Prevalence, disability, and management patterns of migraine in Korea: nationwide survey data from 2009 and 2018;Kim;J Clin Neurol,2021

5. The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates;Stovner;J Headache Pain,2022

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness analysis of rimegepant for on-demand acute treatment of migraine in China;Frontiers in Neurology;2024-08-23

2. New Drug: Rimegepant for migraine;Australian Prescriber;2024-08-20

3. Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration’s adverse event reporting system databases;Frontiers in Pharmacology;2024-07-31

4. Safety of Rimegepant in Adults with Migraine and Cardiovascular Risk Factors: Analysis of a Multicenter, Long-Term, Open-Label Study;Pain and Therapy;2024-07-10

5. Efficacy and Safety of Rimegepant 75 mg Oral Tablet, a CGRP Receptor Antagonist, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial;Journal of Pain Research;2024-07